Sangamo Therapeutics Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Source: seekingalpha
- BLA Submission Progress: Sangamo is advancing the rolling submission of the BLA for ST-920 in Fabry disease, with expectations to complete it as early as this summer, contingent on securing adequate funding, which could open significant market access opportunities for the company.
- Stock Trading Change: Sangamo's common stock has transitioned to trading on the OTCQB market due to noncompliance with NASDAQ's minimum bid requirements, and the company plans to appeal the delisting determination in June, which may impact investor confidence.
- Funding Needs Focus: Management emphasized actively seeking additional capital and evaluating all strategic options to maximize asset value, highlighting the company's dependency on financing in the current market environment.
- FDA Regulatory Dynamics: The FDA confirmed that no additional confirmatory study is required for ST-920, allowing for the submission of 104-week data to support traditional approval, providing greater flexibility and confidence in regulatory approval processes for the company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
